Stelfonta 2ml
Stelfonta (tigilanol tiglate injection) is indicated for use in dogs for the treatment of non-metastatic cutaneous mast cell tumors and non-metastatic subcutaneous mast cell tumors located at or distal to the elbow or the hock. STELFONTA removes 75% of MCTs with a single treatment
STELFONTA is a new intratumoral treatment for dogs registered for the treatment of cutaneous mast cell tumours (MCT) anywhere on the body and subcutaneous MCTs located at or distal to the elbow or the hock.
What is Stelfonta used for?
- Non-metastatic cutaneous (skin) mast cell tumors anywhere on the body.
- Non-metastatic subcutaneous (under the skin) mast cell tumors that are located on the legs, specifically at or below the elbow or hock.
- It is an alternative to surgery for tumors that are hard to remove due to their size or location.
- The total tumor volume must be no more than 10 cm³.
How is Stelfonta administered?
- The dose is calculated based on the tumor's volume, with a maximum dose of 5 ml per dog.
- The drug is injected into the center of the tumor in a "fanning" motion to ensure even distribution.
- The injection causes the tumor to break down, resulting in an open wound that typically heals on its own over several weeks.
Stelfonta Benefits for Dogs
STELFONTA is a simple treatment that provides a high tumour elimination rate, rapid healing, and a speedy return to normal activity for the dog. Stelfonta contains tigilanol tiglate, which works locally by stimulating the immune system, resulting in destruction of the tumour and the tumour’s blood supply, followed by rapid healing of the site with minimal scarring.
STELFONTA starts to work within hours with tumours typically destroyed by day seven. A single treatment destroys the mast cell tumour completely in 75% of observed cases and 87% of tumours with up to two treatments. Complete healing of the resulting wound following tumour destruction by STELFONTA is typically within 6 weeks.
MCTs are the most common form of skin cancer in dogs, accounting for up to 21% of skin cancer cases and until now, surgical removal of the tumour has been standard. However, surgery can pose challenges, such as accessibility of the tumour making it difficult or impossible to obtain sufficient margins that can lead to amputation to fully remove the tumour as well as anaesthetic risks, especially in senior or brachycephalic pets. Many dog owners are also keen to avoid surgery or anaesthesia for their dogs.
Tigilanol tiglate is a biologically active pharmaceutical compound extracted from the seed of the native Australian blushwood (Fontainea picrosperma) tree found in the North Queensland rainforest. Tigilanol tiglate was discovered and developed in Australia and has been extensively researched over many years.
Potential side effects
While most side effects are mild and temporary, some can be severe.
- At the injection site: Swelling, bruising, pain, and eventual wound formation as the tumor breaks down.
- Systemic reactions: Vomiting, diarrhea, lethargy, or decreased appetite.
- Mast cell degranulation: The breakdown of the tumor can cause a systemic inflammatory reaction. To minimize the risk of a severe reaction, dogs are often pre-treated and post-treated with corticosteroids and antihistamines.
Important Considerations
- Refrigeration: Stelfonta vials must be kept refrigerated.
- Safety: Personal protective equipment is required when handling the drug to avoid accidental exposure.
- Metastasis: Stelfonta is not for the treatment of metastatic mast cell tumors, where the cancer has spread.
- Healing: The wound created by the treatment will require care as it heals. Pet owners should monitor for excessive pain, discharge, or signs of infection and contact their vet if concerned.
No comments:
Post a Comment